The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

Schizophrenia Bulletin

Volumn 25, Issue 2, 1999, Pages 233-255

  Meltzer, Herbert Y ^a   McGurk, Susan R ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Clozapine; Cognition; Neuroleptics; Olanzapine; Risperidone

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; AMPEROZIDE; BENZATROPINE; CLONAZEPAM; CLORAZEPATE; CLOZAPINE; DOPAMINE RECEPTOR; FLUOXETINE; HALOPERIDOL; ILOPERIDONE; LEVOTHYROXINE; LITHIUM; LORAZEPAM; MELPERONE; NEUROLEPTIC AGENT; NORADRENALIN; OLANZAPINE; PAROXETINE; PRIMIDONE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN; SERTINDOLE; SERTRALINE; THIORIDAZINE; UNINDEXED DRUG; VALPROIC ACID; ZIPRASIDONE;

ADULT; AMNESIA; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISORIENTATION; DRUG MECHANISM; FEMALE; HUMAN; LEARNING; MALE; NEUROTRANSMISSION; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SPATIAL MEMORY; TARDIVE DYSKINESIA; WORKING MEMORY;

EID: 0032977410     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.schbul.a033376     Document Type: Review

References (114)

1. Abi-Dargham, A.; Laruelle, M.; Aghajanian, G.K.; Charney, D.; and Krystal, J. The role of serotonin in the pathophysiology and treatment of schizophrenia. Journal of Neuropsychiatry and Clinical Neurosciences, 9:1-17, 1997.
2. The Adjutant General's Office, War Department. Army Individual Test Battery: Manual of Directions and Scoring. Washington, DC: The Office, 1944.
3. 2 receptors in rat cerebral cortex. Journal of Neurochemistry, 46:191-197, 1986.
4. Arvanitis, L.A., and Miller, B.G. Multiple fixed dose of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biological Psychiatry, 42(4):233-246, 1997.
5. Beasley, C.M. Jr.; Tollefsen, G.; Tran, P.; Satterlee, W.; Sanger, T.; and Hamilton, S. Olanzapine versus placebo and haloperidol: Acute phase results of the North American doubleblind olanzapine trial. Neuropsychopharmacology, 14:111-123, 1996.
6. Benton, A.L., and Hamsher, K.D. Multilingual Aphasia Examination. Iowa City, IA: University of Iowa, 1976.
7. Berman, K.F.; Zee, R.F.; and Weinberger, D.R. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia: 2. Regional cerebral blood flow (rCBF) evidence. Archives of General Psychiatry, 43:126-135, 1986.
8. Bilder, R.M.; Turkel, E.; Lipschutz-Broch, L.; and Lieberman, J.A. Antipsychotic medication effects on neuropsychological functions. Psychopharmacology Bulletin, 28:353-366, 1992.
9. Braff, D.L.; Heaton, R.; Kuck, J.; Cullum, M.; Moranville, J.; Grant, I.; and Zisook, S. The generalized pattern of neuropsychological deficits in outpatients with chronic schizophrenia with heterogeneous Wisconsin Card Sorting Test results. Archives of General Psychiatry, 48:891-898, 1991.
10. Broersen, L.M.; Heinsbroek, R.P.; de Bruin, J.P.; Joosten, R.N.; van Hest, A.; and Olivier, B. Effects of local application of dopaminergic drugs into the dorsal part of the medial prefrontal cortex of rats in delayed matching to position task: Comparison with local cholinergic blockade. Brain Research, 645(1-2):113-122, 1994.
11. Broersen, L.M.; Heinsbroek, R.P.; de Bruin, J.P.; Uylings, H.B.; and Olivier, B. The role of the medial prefrontal cortex of rats in short-term memory functioning: Further support for involvement of cholinergic, rather than dopaminergic mechanisms. Brain Research, 674(2):221-229, 1995.
12. Broks, P.; Preston, G.C.; Traub, M.; Poppelton, P.; Ward, C.; and Stahl, S.M. Modeling dementia: Effects of scopolamine on memory and attention. Neuropsychologia, 26:685-700, 1988.
13. Buchanan, R.W.; Holstein, C.; and Breier, A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biological Psychiatry, 36:717-725, 1994.
14. Buhot, M.C. Serotonin receptors in cognitive behaviors. Current Opinion in Neurobiology, 7:243-254, 1997.
15. Buschke, H., and Fuld, P.A. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology, 11:1019-1025, 1974.
16. Cassens, G.; Inglis, A.K.; Appelbaum, P.S.; and Guthell, T.G. Neuropsychological function in chronic schizophrenia patients. Schizophrenia Bulletin, 16:477-499, 1990.
17. Daniel, D.G.; Goldberg, T.E.; Weinberger, D.R.; Kleinman, J.E.; Pickar, D.; Lubick, L.J.; and Williams, T.S. Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: A pilot study. American Journal of Psychiatry, 153:417-419, 1996.
18. Davis, J.M., and Casper, R. Antipsychotic drug: Clinical pharmacology and therapeutic use. Drugs, 14:260-282, 1977.
19. Davis, R., and Markham, A. Ziprasidone. CNS Drugs, 8:153-159, 1997.
20. Delis, D.C.; Kramer, J.H.; Kaplan, E.F.; and Ober, B.A. California Verbal Learning Test, Manual. New York: The Psychological Corporation (Harcourt Brace Jovanovich), 1983.
21. Earle-Boyer, E.A.; Serper, M.R.; Davidson, M.; and Harvey, P.D. Continuous performance tests in schizophrenic patients: Stimulus and medication effects on performance. Psychiatry Research, 37:37-46, 1991.
22. Eitan, N.; Levin, Y.; Ben-Artzi, E.; Levy, A.; and Neumann, M. Effects of antipsychotic drugs on memory functions of schizophrenic patients. Acta Psychiatrica Scandinavica, 35:74-76, 1992.
23. Endicott, J., and Spitzer, R.L. The diagnostic interview: The Schedule for Affective Disorders and Schizophrenia (SADS). Archives of General Psychiatry, 35:837-844, 1978.
24. 2-dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine - relation to extrapyramidal side effects. Archives of General Psychiatry, 49:538-544, 1992.
25. Fujii, D.E.; Ahmed, I.; Jokumsen, M.; and Compton, J.M. The effects of clozapine on cognitive functioning in treatment-resistant schizophrenic patients. Journal of Neuropsychiatry and Clinical Neurosciences, 9:240-245, 1997.
26. Galletly, C.A.; Clark, C.R.; McFarlane, A.C.; and Weber, D.L. Relationships between changes in symptoms ratings, neuropsychological test performance, and quality of life in schizophrenic patients with clozapine. Psychiatry Research, 72:161-166, 1997.
27. Gallhofer, B.; Bauer, U.; Lis, S.; Krieger, S.; and Gruppe, H. Cognitive dysfunction in schizophrenia: Comparison of treatment with atypical antipsychotic agents and conventional neuroleptics drugs. European Neuropsychopharmacology, 6:14-20, 1996.
28. Goldberg, T.E.; Greenberg, R.D.; Griffin, S.J.; Gold, J.M.; Kleinman, J.E.; Pickar, D.; Shulz, S.C.; and Weinberger, D.R. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. British Journal of Psychiatry, 162:43-48, 1993.
29. Goldman-Rakic, P.S. Prefrontal cortical dysfunction in schizophrenia: The relevance of working memory. In: Carrol, B.I., and Barrett, J.E., eds. Psychopathology and the Brain. New York, NY: Raven Press Ltd., 1991. pp. 1-21.
30. Goldman-Rakic, P.S., and Selemon, L.D. Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophrenia Bulletin, 23:437-458, 1997.
31. Grace, J.; Bellus, S.P.; Raulin, M.L.; Herz, M.L.; Priest, B.L.; Brenner, V.; Donnelly, K.; Smith, P.; and Gunn, S. Long-term impact of clozapine and psychosocial treatment of psychiatric symptoms and cognitive functioning. Psychiatric Services, 4:41-45, 1996.
32. Green, M.F. What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry, 153:321-330, 1996.
33. Green, M.F.; Kern, R.S.; Williams, O.; McGurk, S.R.; and Lee, K. Procedural learning in schizophrenia: Evidence from serial reaction time. Cognitive Neuropsychiatry, 2(2):123-134, 1996.
34. Green, M.F.; Marshall, B.D., Jr.; Wirshing, W.C.; Ames, D.; Marder, S.R.; McGurk, S.R.; Kern, R.S.; and Mintz, J. Does risperidone improve verbal working memory in schizophrenia? American Journal of Psychiatry, 154:799-804, 1997.
35. Hagger, C.; Buckley, P.; Kenny, J.T.; Freidman, L.; Ubogy, D.; and Meltzer, H.Y. Improvement in cognitive function and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biological Psychiatry, 34:702-712, 1993.
36. Harvey, P.D., and Keefe, R.S.E. Cognitive impairment in schizophrenia and implication of atypical neuroleptic treatment. CNS Spectrums, 2:41-53, 1997.
37. Heaton, R.K. Wisconsin Card Sorting Test Manual. Odessa, FL: Psychological Assesment Resources, 1981.
38. Heaton, R.K., and Crowley, T.J. Effect of psychiatric disorders and their somatic treatments on neuropsychological test results. In: Filskov, S., and Boll, T.J., eds. Handbook of Clinical Neuropsychology. New York, NY: John Wiley & Sons, 1981. pp. 481-525.
39. Hegarty, J.D.; Baldessarini, R.J.; Tohen, M.; Waternaux, C.; and Oepen, G. One hundred years of schizophrenia: A meta-analysis of the outcome literature. American Journal of Psychiatry, 151:1409-1416, 1994.
40. Hoff, A.L.; Faustman, W.O.; Wieneke, M.; Espinoza, S.; Costa, M.; Wolkowitz, O.; and Csernansky, J.C. The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. Neuropsychopharmacology, 15:361-369, 1996.
41. Hoff, A.L.; Riordan, H.; O'Donnell, D.W.; Morris, L.; and DeLisi, L.E. Neuropsychological functioning of first-episode schizophreniform patients. American Journal of Psychiatry, 149:898-903, 1992.
42. Jakab, R.L., and Goldman-Rakic, P.S. 5-Hydroxytryptamine 2A serotonin receptors in the primate cerebral cortex: Possible site of action of hallucinogenic and antipsychotic drugs in pryamidal cell apical dendrites. Proceedings of the National Academy of Sciences of the United States of America, 95: 735-740, 1998.
43. Kane, J.; Honigfeld, G.; Singer, J.; Meltzer, H.; and the Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45:789-796, 1988.
44. Keefe, R.S.E.; Silva, S.G; Perkins, D.O.; and Lieberman, J.A. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis. Schizophrenia Bulletin, 25(2):201-222, 1999.
45. Kenny, J.T., and Meltzer, H.Y. Attention and higher cortical functions in schizophrenia. Journal of Neuropsychiatry and Clinical Neurosciences, 4:269-275, 1991.
46. Kern, R.S.; Green, M.F.; Marshall, B.D.; Wirshing, W.C.; Wirshing, D.; McGurk, S.R.; Marder, S.R.; and Mintz, J. Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients. Biological Psychiatry, 44:726-732, 1998.
47. Kern, R.S.; Green, M.F.; Marshall, B.D.; Wirshing, W.C.; Wirshing, D.; McGurk, S.R.; Marder, S.R.; and Mintz, J. Risperidone vs. haloperidol on secondary memory: Can newer antipsychotics medications aid learning? Schizophrenia Bulletin, 25(2):223-232, 1999.
48. King, D.J. The effect of neuroleptics on cognitive and psychomotor function. British Journal of Psychiatry, 157:799-811, 1990.
49. Kuroki, H.; Meltzer, H.Y.; and Ichikawa, J. Effect of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. Journal of Pharmacology and Experimental Therapeutics, 288:774-781, 1998.
50. Lee, M.A.; Meltzer, H.Y.; and Jayathilake, K. A comparison of the effect of clozapine with typical neuroleptics on cognitive function on neuroleptic responsive schizophrenia. Schizophrenia Research, in press.
51. Lee, M.A.; Thompson, P.; and Meltzer, H.Y. Effects of clozapine on cognitive function in schizophrenia. Journal of Clinical Psychiatry, 55(Suppl. B):8-14, 1994.
52. Lieberman, J.A.; Saltz, B.L.; Johns, C.A.; Pollack, S.; Borenstein, M.; and Kane, J. The effects of clozapine on tardive dyskinesia. British Journal of Psychiatry, 158:503-510, 1991.
53. Lindenmayer, J.P.; Iskander, A.; Park, M.; Apergi, F.S.; Czobor, P.; Smith, R.; and Allen, D. Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenics: A prospective study. Journal of Clinical Psychiatry, 59:521-527, 1998.
54. Lindstrom, E., and von Knorring, L. Changes in single symptoms and separate factors of the schizophrenic syndrome after treatment with risperidone or haloperidol. Pharmacopsychiatry, 27:108-113, 1994.
55. Lindstrom, L.H. The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatrica Scandinavica, 77:524-529, 1988.
56. Lysaker, P.; Bell, M.; and Beam-Goulet, J. Wisconsin Card Sorting Test and work performance in schizophrenia. Psychiatry Research, 56:45-51, 1995.
57. Marder, S.R., and Meibach, R. Risperidone in the treatment of schizophrenia. American Journal of Psychiatry, 151:825-835, 1994.
58. 2 receptor density in rat cerebral cortex. Life Sciences, 45:1397-1406, 1989.
59. McGurk, S.R.; Green, M.G.; Wirshing, W.C.; Ames, D.; Marshall, B.D.; and Marder, S.M. "The Effects of Risperidone vs. Haloperidol on Spatial Working Memory in Treatment-Resistant Schizophrenia." Paper presented at 51st Annual Meeting of the Society of Biological Psychiatry, New York, NY, 1996.
60. McGurk, S.R.; Green, M.F.; Wirshing, W.C.; Ames, D.; Marshall, B.D.; Marder, M.D.; and Mintz, J. The effects of risperidone vs. haloperidol on cognitive functioning in treatment-resistant schizophrenia: The Trail Making Test. CNS Spectrums, 2:60-64, 1997.
61. McGurk, S.R.; Levin, E.D.; and Butcher, L.L. Dopamine modulation of cholinergic mediated memory deficits following lesions of the cholinergic medial pathway. Neuroscience, 50:129-135, 1992.
62. Meltzer, H.Y. Dimensions of outcome with clozapine. British Journal of Psychiatry, 160 (Suppl. 17):46-53, 1992.
63. Meltzer, H.Y. The concept of antipsychotic drugs. In: den Boer, J.A.; Westenberg, H.G.M.; and van Praag, H.M., eds. Advances in the Neurobiology of Schizophrenia. Vol. 1. London, England: Wiley & Sons, 1995a, pp. 265-273.
64. Meltzer, H.Y. Multiple outcome criteria in schizophrenia: An overview of outcome with clozapine. European Psychiatry, 19 (Suppl. 10):19S-25S, 1995b.
65. Meltzer, H.Y. Treatment-resistant schizophrenia - The role of clozapine. Current Medical Research and Opinion, 14(1):1-20, 1997.
66. Meltzer, H.Y., and Fatemi, S.H. The role of serotonin in schizophrenia and the mechanism of action of antipsychotic drugs. In: Kane, J.M.; Möller, H.Y.; and Awouters, F., eds. Serotonin in Antipsychotic Treatment: Mechanisms and Clinical Practice. New York, NY: Marcel Dekker, Inc., 1996. pp. 77-107.
67. Meltzer, H.Y.; Goode, D.J.; Schyve, P.M.; Young, M.; and Fang, V.S. Effect of clozapine on human serum prolactin levels. American Journal of Psychiatry, 136:1550-1555, 1979.
68. Meltzer, H.Y.; Lee, M.; and McGurk, S.R. Effects of risperidone on cognitive function in schizophrenic patients. In preparation.
69. Meltzer, H.Y.; Matsubara, S.; and Lee, M. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2, and serotonin 2 pKi values. Journal of Pharmacology and Experimental Therapeutics, 251:238-246, 1989.
70. Meltzer, H.Y.; Thompson, P.A.; Lee, M.A.; and Ranjan, R. Neuropsychologic deficits in schizophrenia: Relation to social function and effect of antipsychotic drug treatment. Neuropsychopharmacology, 14(35):275-335, 1996.
71. Meyer-Lindenberg, A.; Gruppe, H.; Bauer, U.; Lis, S.; Krieger, S.; and Gallhofer, B. Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: Results from a double-blind study. Pharmacopsychiatry, 30(2): 35-42, 1997.
72. Miller, R.J., and Hiley, C.R. Anti-muscarinic properties of neuroleptics and drug-induced Parkinsonism. Nature, 248(449):596-597, 1974.
73. Mortimer, A.M. Cognitive function in schizophrenia-Do neuroleptics make a difference? Pharmacology, Biochemistry and Behavior, 56:789-795, 1997.
74. Mulkern, V.M., and Manderscheid, R.W. Characteristics of community support program clients in 1980 and 1984. Hospital and Community Psychiatry, 40:165-172, 1989.
75. Murphy, B.L.; Roth, R.H.; and Arnsten, A.F. Clozapine reverses the spatial working memory deficits induced by FG7142: Clozapine reverses the spatial working deficits induced by FG7142 in monkeys. Neuropharmacology, 16:433-437, 1997.
76. Newcombe, F. Missile Wounds of the Brain. New York, NY: Oxford University Press, 1969.
77. Nyberg, S.; Farde, L.; Eriksson, L.; Halldin, C.; and Eriksson, B. 5-HT2 and D2 dopamine receptor occupancy in the living human brain: A PET study with risperidone. Psychopharmacology, 110:265-272, 1993.
78. Nyberg, S.; Farde, L.; and Halldin, C. A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology, 16:1-7, 1997.
79. 4 receptor. British Journal of Pharmacology, 122:401-408, 1997.
80. Overall, J.E., and Gorham, D.R. The Brief Psychiatric Rating Scale. Psychological Reports, 10:799-812, 1962.
81. Parada, M.A.; Hernandez, L.; Puig de Parada, M.; Rada, P.; and Murzi, E. Selective action of acute systemic clozapine on acetylcholine release in the rat prefrontal cortex by reference to the nucleus accumbens and striaturn. Journal of Pharmacology and Experimental Therapeutics, 281:582-588, 1997.
82. Peroutka, J.S., and Snyder, S.H. Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. Science, 210:88-90, 1980.
83. Peterson, L.R., and Peterson, MJ. Short-term retention of individual verbal items. Journal of Experimental Psychology, 58:193-198, 1959.
84. Peuskens, J. Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. British Journal of Psychiatry, 166:712-733, 1995.
85. Pfeiffer, C., and Wagner, M.L. Clozapine therapy for Parkinson's disease and other movement disorders. American Journal of Hospital Pharmacy, 51:3047-3053, 1994.
86. Rossi, A.; Mancini, F.; Stratta, P.; Mattei, P.; Gismondi, R.; Pozzi, F.; and Casacchia, M. Risperidone, negative symptoms, and cognitive deficit in schizophrenia: An open study. Acta Psychiatrica Scandinavica, 95:40-43, 1997.
87. 1c receptors. Journal of Pharmacology and Experimental Therapeutics, 260:1361-1378, 1992.
88. Roth, B.L.; Craigo, S.C.; Choudhary, M.S.; Uler, A.; Monsma, F.J.; Shen, Y.; Meltzer, H.Y.; and Sibley, D.R. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine 6 (5-HT6) and 5-HT hydroxytryptamine 7 (5-HT7) receptors. Journal of Pharmacology and Experimental Therapeutics, 268:1406-1410, 1994.
89. Roth, B.L.; Tandra, S.; Burgess, L.H.; Sibley, D.R.; and Meltzer, H.Y. D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology, 120:365-368, 1995.
90. Rupp, A., and Keith, S. The costs of schizophrenia. Psychiatric Clinics of North America, 16:413-423, 1993.
91. Sarter, M., and Bruno, J.P. Cognitive functions of cortical acetylcholine: Toward a unifying hypothesis. Brain Research - Brain Research Reviews, 23(1-2):28-46, 1997.
92. Sawaguchi, T., and Goldman-Rakic, S. D1 dopamine receptors in prefrontal cortex: Involvement in working memory. Science, 251:947-950, 1991.
93. Saykin, A.J.; Shtasel, D.L.; Gur, R.E.; Kester, D.B.; Mozley, L.H.; Stafiniak, P.; and Gur, R.C. Neuropsychological deficits in neuroleptic naïve patients with first-episode schizophrenia. Archives of General Psychiatry, 51(2):124-131, 1994.
94. Scholz, E., and Dichgans, J. Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. European Archives of Psychiatry and Neurological Science, 235:60-64, 1985.
95. Schotte, A.; Janssen, P.F.M.; Gommeren, W.; Luyten, W.; Van Grompel, P.; Lesage, A.S.; De Loore, K.; and Leysen, J.E. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology, 124:57-73, 1996.
96. Seeger, T.F.; Seymour, P.A.; Schmidt, A.W.; Zorn, S.H.; Schulz, D.W.; Lebel, L.A.; McLean, S.; Guanowsky, V.; Howard, H.R.; and Lowe, J.A., III. Ziprasidone (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity. Journal of Pharmacology and Experimental Therapeutics, 275:101-113, 1995.
97. Simpson, G.M., and Lindenmayer, J.P. Extrapyramidal symptoms in patients treated with risperidone. Journal of Clinical Psychopharmacology, 17:194-201, 1997.
98. Spohn, H.E., and Strauss, M.E. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. Journal of Abnormal Psychology, 98:367-380, 1989.
99. Stipp, E., and Lussier, I. The effect of risperidone on cognition in patients with schizophrenia. Canadian Journal of Psychiatry, 41(Suppl. 2):S35-S40, 1996.
100. Stockmeier, C.A.; DiCarlo, J.J.; Zhang, Y.; Thompson, P.; and Meltzer, H.Y. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin 2 and dopamine 2 receptors. Journal of Pharmacology and Experimental Therapeutics, 266:1374-1384, 1993.
101. Tandon, R.; Harrigan, E.; and Zorn, S.H. Ziprasidone: A novel antipsychotic with unique pharmacology and therapeutic potential. Journal of Serotonin Research, 4:159-177, 1997.
102. Tohen, M.; Stoll, A.L.; Strakowski, S.M.; Fadedda, G.I.; Mayer, P.V.; Goodwin, D.C.; Kolbrener, M.L.; and Madigan, A.M. The McLean First-Episode Psychosis Project: Six-month recovery and recurrence outcome. Schizophrenia Bulletin, 18:273-282, 1997.
103. Tollefson, G.D.; Beasley, C.M.; Tamura, R.N.; Tran, P.V.; and Potvin, J.H. Blind, controlled long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. American Journal of Psychiatry, 154:1248-1254, 1997a.
104. Tollefson, G.D.; Beasley, C.M., Jr.; Tran, P.V.; Street, J.S.; Krueger, J.A.; Tamura, R.N.; Graffeo, K.A.; and Thieme, M.E. Olanzepine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial. American Journal of Psychiatry, 154:457-465, 1997b.
105. Tran, P.; Hamilton, S.H.; Kuntz, A.J.; Ptovin, J.H.; Andersen, S.W.; Beasley, C.; and Tollefson, G.D. Double-blind comparison of olanzapine vs. risperidone in the treatment of schizophrenia and other psychotic disorders. Journal of Clinical Psychopharmacology, 17:407-418, 1997.
106. Velligan, D.I.; Mahurin, R.K.; Diamond, P.L.; Hazelton, B.C.; Eckert, S.L.; and Miller, A.L. The functional significance of symptomatology and cognitive function in schizophrenia. Schizophrenia Research, 25:21-31, 1997.
107. Watanabe, M.; Kodama, T.; and Hikosaka, K. Increase of extracellular dopamine in primate frontal cortex during a working memory task. Journal of Neurophysiology, 78:2795-2798, 1997.
108. Wechsler, D. Wechsler Intelligence Scale for Children-Revised. New York, NY: Psychological Corporation, 1974.
109. Wechsler, D. WAIS-R Manual. New York, NY: Psychological Corporation, 1981.
110. Weinberger, D.R.; Berman, K.F.; and Zee, R.F. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia: 1. Regional cerebral blood flow (fCBF) evidence. Archives of General Psychiatry, 43:114-125, 1986.
111. Williams, G.V., and Goldman-Rakic, P.S. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature, 376:572-575, 1995.
112. 2a receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse, 27:79-82, 1997.
113. Zahn, T.P.; Pickar, D.; and Haier, R.J. Effects of clozapine, fluphenazine, and placebo on reaction time measures of attention and sensory dominance in schizophrenia. Schizophrenia Research, 13(2):133-144, 1994.
114. Zorn, S.H.; Jones, S.B.; Ward, K.M.; and Liston, D.R. Clozapine is a potent and selective muscarinic M4 receptor agonist. European Journal of Pharmacology, 269(3):R1-R2, 1994.